Canary Fund

CANARY FOUNDATION IS THE WORLD'S FIRST NON-PROFIT ORGANIZATION DEDICATED SOLELY TO THE FUNDING, DISCOVERY AND DEVELOPMENT OF TESTS FOR EARLY CANCER DETECTION.

CANARY SCIENTIFIC PROGRAMSCANARY IS THE WORLDS ONLY NON-PROFIT FOCUSED SOLELY ON EARLY CANCER DETECTION. WE HAVE MULTIDISCIPLINARY SCIENCE TEAMS FOCUSED ON BLOOD-BASED BIOMARKERS OR BIOLOGICAL FINGERPRINTS THAT SHOW THE PRESENCE OR PROGRESS OF DISEASE. WERE PAIRING THOSE BIOMARKERS WITH ADVANCED IMAGING TECHNOLOGIES THAT WILL HELP US VISUALIZE A CANCER TYPE WITH MORE SENSITIVITY AND SPECIFICITY. OUR CLINICAL PROGRAMS COVER TUMORS ACROSS FIVE CANCER TYPES: BREAST, LUNG, OVARIAN, PANCREAS, AND PROSTATE. AND TO FURTHER ENSURE OUR SUCCESS, WE FUNDED THE CANARY CENTER AT STANFORD FOR CANCER EARLY DETECTION, A WORLD-CLASS FACILITY THAT HOPES TO SAVE LIVES THROUGH EARLY DETECTION.

CANARY BREAST CANCER PROGRAMTHE BREAST CANCER PROGRAM IS WORKING TO IMPROVE EARLY DETECTION OF POTENTIALLY LETHAL BREAST CANCER BY IDENTIFYING BIOMARKERS THAT COMPLEMENT EXISTING IMAGING METHODS AND BY DEVELOPING NEW IMAGING ALTERNATIVES. THE BREAST CANCER PROGRAM IS FOCUSED AT STANFORD AND COMBINES EXPERTISE IN BREAST CANCER CARE, IN BREAST IMAGING, AND IN STUDYING PROTEOMIC AND GENE EXPRESSION CHANGES IN THE BODY IN RESPONSE TO DISEASE. ADDITIONAL WORK AIMS TO IDENTIFY BIOMARKERS THAT DISTINGUISH WOMEN WITH CANCER FROM THOSE WITH BENIGN CONDITIONS (SUCH AS A CYST). THESE BIOMARKERS WOULD POTENTIALLY REDUCE THE NUMBER OF UNNECESSARY INVASIVE FOLLOW-UP TESTS AND ENHANCE THE INTERPRETATION OF MAMMOGRAPHIC IMAGES FOR EARLY DETECTION OF BREAST CANCER. NEW IMAGING APPROACHES MAY PROVIDE A MORE SENSITIVE AND MORE ACCURATE APPROACH FOR THE

DETECTION OF BREAST CANCERS. WE ARE TESTING SEVERAL IMAGING ALTERNATIVES, INCLUDING A NEW PET IMAGING AGENT, ENHANCED ULTRASOUND USING TARGETED MICROBUBBLES, AND PHOTOACOUSTIC IMAGING, FOR THEIR ABILITY TO IDENTIFY BREAST CANCER EARLY AND TO BETTER DISTINGUISH CANCER AND BENIGN CONDITIONS.CANARY OVARIAN CANCER PROGRAMTHE GOAL OF OUR OVARIAN RESEARCH PROGRAM IS TO DEVELOP A STRATEGY TO ACCURATELY IDENTIFY OVARIAN CANCERS THAT WOULD OTHERWISE BE LETHAL AT A STAGE WHEN THEY ARE READILY CURABLE. OUR VISION IS OF A TWO-STAGE SCREENING STRATEGY, CONSISTING OF A SIMPLE BLOOD TEST FOLLOWED BY A MOLECULAR IMAGING TEST. DEVELOPMENT OF BLOOD AND IMAGING TESTS FOLLOWS A SIMILAR ROADMAP; BOTH INCLUDE (CONTINUED ON SCHEDULE O)